Promoter methylation of tumor-related genes as a potential biomarker using blood samples for gastric cancer detection

作者：Jinfeng Wen, Tuo Zheng, Kefeng Hu, Chunxia Zhu, Lihua Guo, Guoliang Ye · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.20782 · 被引用次数：23 · 研究领域：Epigenetics and DNA Methylation、RNA modifications and cancer、Ferroptosis and cancer prognosis

// Jinfeng Wen 1 , Tuo Zheng 2 , Kefeng Hu 1 , Chunxia Zhu 1 , Lihua Guo 1 and Guoliang Ye 1 1 Department of Gastroenterology, The Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315020, People’s Republic of China 2 Department of Gastroenterology, Ningbo No.1 Hospital, Ningbo, Zhejiang 315000, People’s Republic of China Correspondence to: Guoliang Ye, email: ndfyygl@163.com Keywords: tumor-related gene, promoter methylation, blood, GC, diagnosis Received: July 02, 2017     Accepted: July 30, 2017     Published: September 08, 2017 ABSTRACT Gene promoter methylation has been reported in gastric cancer (GC). However, the potential applications of blood-based gene promoter methylation as a noninvasive biomarker for GC detection remain to be evaluated. Hence, we performed this analysis to determine whether promoter methylation of 11 tumor-related genes could become a promising biomarker in blood samples in GC. We found that the cyclin-dependent kinase inhibitor 2A ( p16 ), E-cadherin ( CDH1 ), runt-related transcription factor 3 ( RUNX3 ), human mutL homolog 1 ( MLH1 ), RAS association domain family protein 1A ( RASSF1A ), cyclin-dependent kinase inhibitor 2B ( p15 ), adenomatous polyposis coli ( APC ), Glutathione S-transferase P1 ( GSTP1 ), TP53 dependent G2 arrest mediator candidate ( Reprimo ), and O6-methylguanine-DNAmethyl-transferase ( MGMT ) promoter methylation was notably higher in blood sam...